Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Peter_Maag
|
| gptkbp:clinicalTrialPhase |
Phase 1
Phase 2 |
| gptkbp:collaboratesWith |
gptkb:National_Institutes_of_Health
gptkb:Gilead_Sciences |
| gptkbp:developedBy |
KYV-101
KYV-201 |
| gptkbp:focusesOn |
autoimmune diseases
gene therapy |
| gptkbp:foundedYear |
2018
|
| gptkbp:headquartersLocation |
gptkb:Emeryville,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Kyverna Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
KYTX
|
| gptkbp:technology |
gene therapy
|
| gptkbp:therapeuticArea |
neurology
nephrology rheumatology |
| gptkbp:website |
https://www.kyvernatx.com/
|
| gptkbp:bfsParent |
gptkb:Beth_Seidenberg
|
| gptkbp:bfsLayer |
7
|